16-Mar-2026
Axogen's Revenue Surges on FDA Milestone, Reimbursement Wins, and Improved Cash Flow
Market Chameleon (Tue, 24-Feb 2:56 AM ET)
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
Globe Newswire (Tue, 24-Feb 7:00 AM ET)
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Globe Newswire (Tue, 17-Feb 7:00 AM ET)
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Globe Newswire (Tue, 10-Feb 7:00 AM ET)
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
Globe Newswire (Wed, 21-Jan 11:18 PM ET)
Axogen Announces Proposed Public Offering of Common Stock
Globe Newswire (Wed, 21-Jan 4:09 PM ET)
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
Globe Newswire (Mon, 12-Jan 7:00 AM ET)
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference
Globe Newswire (Wed, 17-Dec 7:00 AM ET)
Market Chameleon (Thu, 4-Dec 5:03 AM ET)
Market Chameleon (Thu, 4-Dec 2:50 AM ET)
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Axogen trades on the NASDAQ stock market under the symbol AXGN.
As of March 16, 2026, AXGN stock price climbed to $32.84 with 1,149,966 million shares trading.
AXGN has a beta of 1.48, meaning it tends to be more sensitive to market movements. AXGN has a correlation of 0.13 to the broad based SPY ETF.
AXGN has a market cap of $1.65 billion. This is considered a Small Cap stock.
Last quarter Axogen reported $60 million in Revenue and $.07 earnings per share. This beat revenue expectation by $4,500 and exceeded earnings estimates by $.03.
In the last 3 years, AXGN traded as high as $36.00 and as low as $3.45.
The top ETF exchange traded funds that AXGN belongs to (by Net Assets): VTI, IWM, VXF, IWO, FESM.
AXGN has outperformed the market in the last year with a price return of +91.4% while the SPY ETF gained +22.6%. AXGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.1% and +3.5%, respectively, while the SPY returned -1.6% and -2.5%, respectively.
AXGN support price is $31.22 and resistance is $33.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AXGN shares will trade within this expected range on the day.